Tracing temporal and spatial progression of HD is essential to design therapeutics.
We analyze subcortical gray matter shape and DTI in 296 premanifest HD individuals.
Changes in the shape of deep gray matter occur since the very early premanifest stages.
The in-vivo mapping of brain differences potentially indicate when and where therapeutics could be targeted.